Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX103 CAR-T Cell Injection in Recurrent or Progressive Grade 4 Glioma
NCT06482905Phase 1Recruiting
- Sponsor
- Tcelltech GmbH
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 1, open-label trial of tx-103 in glioma (3 arms), sponsored by Tcelltech GmbH. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 6 months. Started Sep 2024; status: recruiting.
02
Drugs
tx-103
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06482905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482905.